Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.